Skip to main content
OpenTrials
Completed

NCT Number: NCT00310934

A Stepwise Strategy Utilizing Buprenorphine and Methadone

The objective of this study is to compare optimally given methadone maintenance treatment (MMT) for heroin dependence with a novel, sequential strategy, where patients are offered buprenorphine as first line treatment, allowed dose adjustments as needed, and switched to methadone if the maximal dose of buprenorphine is insufficient.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Dept of Clinical Neuroscience, Karolinska Inst

Stockholm, 14176, Sweden

About this study

The objective of this study is to compare optimally given methadone maintenance treatment (MMT) for heroin dependence with a novel, sequential strategy (STEP), where patients are offered buprenorphine as first line treatment, allowed dose adjustments as needed, and switched to methadone if the maximal dose of buprenorphine is insufficient.

For this purpose, 96 subjects at two centers (Uppsala and Stockholm) are randomized to MMT or STEP and followed for 6 months. Retention in treatment is the primary outcome. Secondary outcomes in completers are proportion urine samples free of illicit opiates on app. twice weekly sampling, and problem severity as measured by a semistructured interview, the Addiction Severity Index (ASI) at baseline and after 3 and 6 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Heroin dependence according to DSM IV > 1year
  • Age > 20 years
  • Acceptance of the stated treatment principles.

Exclusion criteria

  • Severe psychiatric illness such as dementia or psychosis compromising the patient's ability to provide informed consent
  • Other clinically significant psychiatric illness unless stable under treatment
  • Severe medical condition such as advanced lung disease, unstable cardiovascular disease, severe liver disease
  • Other clinically significant medical condition unless stable under treatment
  • Treatment with anti-seizure drugs or disulfiram
  • Pregnancy or intent to become pregnant within the next year
  • Ongoing nursing
  • Patients involuntarily discharged from a methadone or buprenorphine maintenance program within the last 3 months not eligible.

Treatment and study plan

Methadone

Drug

buprenorphine / methadone sequence

Drug

Relapse prevention

Behavioral

Contingency Management

Behavioral

Primary outcomes

  1. Retention in treatment

Secondary outcomes

  1. Proportion urine samples free of illicit drugs

  2. Problem severity as measured by Addiction Severity Index

Sponsors and collaborators

Lead sponsor

Karolinska University Hospital

Other

Collaborators

  • Region Stockholm
  • Schering-Plough
  • Swedish National Drug Policy Coordinator

Registry information

Official study title

Graded Strategy for Pharmacological Treatment of Heroin Dependence

Important dates

Study start
2005
Study completion
2006
First posted
Apr 5, 2006
Registry last updated
Oct 24, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.